Bone Cancer

CONCLUSIONS This case illustrates 3 critical clinical lessons: (1) NOF in adults requires heightened suspicion for aggressive bone tumors due to atypical imaging features and absence of expected involution; (2) Biopsy is mandatory for radiologically indeterminate lesions to avoid misdiagnosis and overtreatment; and (3) Surgical indication in adult NOF should be based on lesion size (>33 mm), cortical integrity, and fracture risk rather than symptoms alone. Prophylactic stabilization with bone cement provides immediate mechanical strength in mature bone.

Ki-67 labeling was confined to a subset of cytokeratin-positive cells at the periphery of the nodules, indicating that peripheral proliferation contributes to the exophytic growth pattern. This report describes a case of cervical chordoma with a unique exophytic presentation in a ferret.

This case highlights everolimus-associated hypertriglyceridemia in a lung transplant recipient and underscores the need for tight lipid monitoring and early immunosuppression adjustment when severe dyslipidemia emerges.

P4, N=60, West China Hospital , Sichuan University; West China Hospital , Sichuan University

This case is discussed within the context of a comprehensive narrative review highlighting the distinct biological behavior of calvarial GCTB compared to skull-base lesions, the critical importance of achieving gross total resection, and the emerging role of molecular diagnosis (H3F3A G34W mutation) and adjuvant therapies including denosumab. Calvarial GCTB offers superior surgical accessibility and prognosis compared to skull-base counterparts, with appropriately aggressive resection typically achieving cure without need for radiotherapy, thereby avoiding the well-documented risk of radiation-induced malignant transformation.

Our case emphasises that intra-articular NF is a rare entity that can mimic more common intra-articular tumours. The detection of USP6 on histopathological analysis allows accurate diagnosis and treatment.

OS-H3F3A showed significant heterogeneity in morphological features and clinical behavior. We recommend routine screening for these tumors.

P2, N=20, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting --> Recruiting

P2, N=27, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=40 --> 27

P1/2, N=49, Active, not recruiting, Susan Chi, MD | Recruiting --> Active, not recruiting

Molecular insights have identified key drivers, including Brachyury [T-box transcription factor T (TBXT)], receptor tyrosine kinases, and emerging biomarkers that may guide future therapeutic selection. Integrated multimodal care is critical for improving survival and function in patients with sacral chordomas.